https://stage.mediaroom.com/sanoficanada2/ https://stage.mediaroom.com/sanoficanada2/2026-04-09-Sanofi-becomes-market-authorization-holder-for-Nuvaxovid-R-in-Canada,-expanding-COVID-19-vaccine-choices-for-Canadians Thu, 09 Apr 2026 13:28:00 -0400 https://stage.mediaroom.com/sanoficanada2/2026-04-09-Sanofi-becomes-market-authorization-holder-for-Nuvaxovid-R-in-Canada,-expanding-COVID-19-vaccine-choices-for-Canadians https://stage.mediaroom.com/sanoficanada2/2026-02-03-Rezurock-R-now-reimbursed-in-Ontario-and-British-Columbia-for-people-living-with-chronic-graft-versus-host-disease-GVHD Tue, 03 Feb 2026 08:00:00 -0500 https://stage.mediaroom.com/sanoficanada2/2026-02-03-Rezurock-R-now-reimbursed-in-Ontario-and-British-Columbia-for-people-living-with-chronic-graft-versus-host-disease-GVHD https://stage.mediaroom.com/sanoficanada2/2025-11-10-Eight-out-of-10-infants-and-newborns-in-Canada-have-access-to-RSV-prevention-with-Beyfortus-R-this-season Mon, 10 Nov 2025 13:30:00 -0500 https://stage.mediaroom.com/sanoficanada2/2025-11-10-Eight-out-of-10-infants-and-newborns-in-Canada-have-access-to-RSV-prevention-with-Beyfortus-R-this-season https://stage.mediaroom.com/sanoficanada2/2025-11-06-Rezurock-R-now-covered-in-Quebec-for-people-living-with-chronic-graft-versus-host-disease-GVHD Thu, 06 Nov 2025 07:00:00 -0500 https://stage.mediaroom.com/sanoficanada2/2025-11-06-Rezurock-R-now-covered-in-Quebec-for-people-living-with-chronic-graft-versus-host-disease-GVHD https://stage.mediaroom.com/sanoficanada2/2025-11-03-Dupixent-R-approved-in-Canada-as-targeted-therapy-for-chronic-spontaneous-urticaria-CSU Mon, 03 Nov 2025 11:22:00 -0500 https://stage.mediaroom.com/sanoficanada2/2025-11-03-Dupixent-R-approved-in-Canada-as-targeted-therapy-for-chronic-spontaneous-urticaria-CSU